RÉSUMÉ
Four decades ago, U.S. life expectancy was within the same range as other high-income peer countries. However, during the past decades, the United States has fared worse in many key health domains resulting in shorter life expectancy and poorer health-a health disadvantage. The National Heart, Lung, and Blood Institute convened a panel of national and international health experts and stakeholders for a Think Tank meeting to explore the U.S. health disadvantage and to seek specific recommendations for implementation research opportunities for heart, lung, blood, and sleep disorders. Recommendations for National Heart, Lung, and Blood Institute consideration were made in several areas including understanding the drivers of the disadvantage, identifying potential solutions, creating strategic partnerships with common goals, and finally enhancing and fostering a research workforce for implementation research. Key recommendations included exploring why the United States is doing better for health indicators in a few areas compared with peer countries; targeting populations across the entire socioeconomic spectrum with interventions at all levels in order to prevent missing a substantial proportion of the disadvantage; assuring partnership have high-level goals that can create systemic change through collective impact; and finally, increasing opportunities for implementation research training to meet the current needs. Connecting with the research community at large and building on ongoing research efforts will be an important strategy. Broad partnerships and collaboration across the social, political, economic, and private sectors and all civil society will be critical-not only for implementation research but also for implementing the findings to have the desired population impact. Developing the relevant knowledge to tackle the U.S. health disadvantage is the necessary first step to improve U.S. health outcomes.
Sujet(s)
Recherche biomédicale , Maladies cardiovasculaires/prévention et contrôle , Longévité/physiologie , National Heart, Lung, and Blood Institute (USA) , Guides de bonnes pratiques cliniques comme sujet , Congrès comme sujet , Humains , États-UnisRÉSUMÉ
Sex and gender have been demonstrated to influence all domains of health, from basic mechanisms of disease development to health service utilization. It is therefore no longer acceptable to ignore sex and gender issues in health research reports if these reports are to be deemed accurate. Funding agencies and journals have been identified as primary change agents in health research systems. Canada is making progress on the funding side of the equation--applicants to Canada's federal health research funding agency are required to justify why sex and gender are relevant or not to their research designs. We argue that it is now time for Canada's leading health research journals to follow suit. We have a unique opportunity in Canada to demonstrate leadership in doing science better with sex and gender--and we should not let it be missed.
Sujet(s)
Recherche biomédicale/organisation et administration , Leadership , Périodiques comme sujet/normes , Canada , Femelle , Humains , Mâle , Plan de rechercheRÉSUMÉ
Growth hormone (GH) secretion in male rats exhibits a 3.3 h ultradian rhythm generated by the reciprocal interaction of GH-releasing hormone (GHRH) and somatostatin (SRIF). SRIF receptor subtypes sst(1) and sst(2) are highly expressed in GHRH neurons of the hypothalamic arcuate nucleus (ARC). We previously demonstrated an ultradian oscillation in binding of SRIF analogs to the ARC in relation to GH peaks and troughs. Here we tested the hypothesis that these ultradian changes in SRIF binding are due to differential plasma membrane targeting of sst(1) receptors in ARC neurons using immunocytochemistry and electron microscopy. We found that 87% of sst(1)-positive ARC neurons also synthesized GHRH. Subcellularly, 80% of sst(1) receptors were located intracellularly and 20% at the plasma membrane regardless of GH status. However, whereas 30% of the cell-surface sst(1) receptors were located perisynaptically or subsynaptically following exposure to high GH secretion, this fraction was increased to 42% following a GH trough period (p = 0.05). Furthermore, the relative abundance of symmetric and asymmetric synapses on sst(1)-positive dendrites also varied significantly, depending on the GH cycle, from approximately equal numbers following GH troughs to 70:30 in favor of symmetric, i.e., inhibitory, inputs after GH peaks (p < 0.02). These findings suggest that postsynaptic localization of sst(1) receptors and synaptic connectivity in the ARC undergo pronounced remodeling in parallel with the GH rhythm. Such synaptic plasticity may be an important mechanism by which sst(1) mediates SRIF's cyclical effects on ARC GHRH neurons to generate the ultradian rhythm of GH secretion.
Sujet(s)
Cycles d'activité/physiologie , Noyau arqué de l'hypothalamus/métabolisme , Hormone de libération de l'hormone de croissance/sang , Hormone de croissance/sang , Neurones/métabolisme , Récepteur somatostatine/métabolisme , Synapses/métabolisme , Animaux , Noyau arqué de l'hypothalamus/ultrastructure , Technique d'immunofluorescence , Immunohistochimie , Mâle , Microscopie électronique , Neurones/ultrastructure , Dosage radioimmunologique , Rats , Rat Sprague-Dawley , Somatostatine/sang , Synapses/ultrastructureRÉSUMÉ
The somatostatin [somatotropin release-inhibiting factor (SRIF)] receptor subtypes sst(2A) and sst(5) are frequently coexpressed in SRIF-responsive cells, including endocrine pituitary cells. We previously demonstrated that sst(2A) and sst(5) exhibit different subcellular localizations and regulation of cell surface expression, although they have similar signaling properties. We investigated here whether sst(2A) and sst(5) functionally interact in cells coexpressing the two receptor subtypes. We stimulated both transfected cells stably expressing sst(2A) alone (CHO-sst(2A)) or together with sst(5) (CHO-sst(2A+5)) and the pituitary cell line AtT20, which endogenously expresses the two receptor subtypes, with either the nonselective agonist [D-Trp(8)]-SRIF-14 or the sst(2)-selective agonist L-779,976. In CHO-sst(2A) cells, stimulation with either ligand resulted in the loss of approximately 75% of cell surface SRIF binding sites and massive internalization of sst(2A) receptors. The cells were desensitized to subsequent stimulation with [D-Trp(8)]-SRIF-14, which failed to inhibit forskolin-evoked cAMP accumulation. Similarly, in CHO-sst(2A+5) and AtT20 cells, [D-Trp(8)]-SRIF-14 induced the loss of 60-70% of SRIF binding sites as well as massive sst(2A) endocytosis. By contrast, in cells expressing both sst(2A) and sst(5), selective stimulation of sst(2A) with L-779,976 resulted in only 20-40% loss of cell surface binding and markedly reduced sst(2A) internalization. Consequently, whereas CHO-sst(2A+5) and AtT20 cells stimulated with [D-Trp(8)]-SRIF-14 were desensitized to a second stimulation with the same agonist, cells prestimulated with L-779,976 were not desensitized to subsequent [D-Trp(8)]-SRIF-14 stimulation. These findings indicate that the presence of sst(5) in the same cells modulates trafficking and cell surface regulation of sst(2A) and cellular desensitization to the effects of SRIF.
Sujet(s)
Endocytose/physiologie , Transport des protéines/physiologie , Récepteur somatostatine/métabolisme , Amides/métabolisme , Amides/pharmacologie , Animaux , Cellules CHO , Colforsine/pharmacologie , Cricetinae , Cricetulus , AMP cyclique/métabolisme , Indoles/métabolisme , Indoles/pharmacologie , Radio-isotopes de l'iode , Souris , Dosage par compétition , Récepteur somatostatine/agonistes , Récepteur somatostatine/génétique , Transduction du signal/physiologie , Somatostatine/analogues et dérivés , Somatostatine/métabolisme , Somatostatine/pharmacologie , TransfectionRÉSUMÉ
Neurotensin (NT) receptors NTS1 and NTS2 are known to display considerable distributional overlap in mammalian central nervous system (CNS). Using co-immunoprecipitation approaches, we demonstrated here that NTS1 forms constitutive heterodimers with NTS2 in transfected COS-7 cells. We also showed that co-expression of NTS2 with NTS1 markedly decreases the cell surface density of NTS1 without affecting ERK1/2 MAPK activity or NT-induced NTS1 internalization. However, radioligand-binding studies indicated that upon prolonged NT stimulation, cell surface NTS1 receptors are more resistant to down-regulation in cells co-expressing NTS1 and NTS2 than in cells expressing NTS1 alone. Taken together, these data suggest that NTS1/NTS2 heterodimerization affects the intracellular distribution and trafficking of NTS1 by making it more similar to that of NTS2 as witnessed in cells expressing NTS2 alone. NTS1/NTS2 heterodimerization might therefore represent an additional mechanism in the regulation of NT-triggered responses mediated by NTS1 and NTS2 receptors.
Sujet(s)
Récepteur neurotensine/métabolisme , Récepteur neurotensine/physiologie , Animaux , Cellules COS , Chlorocebus aethiops , Dimérisation , Régulation négative , Système de signalisation des MAP kinases/physiologie , Microscopie confocale , Transport des protéines , Rats , Récepteur neurotensine/biosynthèse , TransfectionRÉSUMÉ
The aim of the present study was to examine the cellular and sub-cellular distribution of the somatostatin (SRIF) receptor subtype sst1 in the rat hypothalamus. Receptors were immunolabeled using an antibody directed against an antigenic sequence in the N-terminus of the receptor. Immunopositive neuronal cell bodies and dendrites were observed throughout the mediobasal hypothalamus, including the medial preoptic area, paraventricular, periventricular, and arcuate nuclei. Immunoreactive axons and axon terminals were also observed in the median eminence, suggesting that sst1 is also located pre-synaptically. Electron microscopic examination of the arcuate nucleus revealed a predominant association of immunoreactive sst1 with perikarya and dendrites. Most immunoreactive receptors were intracellular and localized to tubulovesicular compartments and organelles such as the Golgi apparatus, but 14% were associated with the plasma membrane. Of the latter, 47% were apposed to abbuting afferent axon terminals and 20% localized immediately adjacent to an active synaptic zone. These results demonstrate a widespread distribution of sst1 receptors in rat hypothalamus. They also show that somatodendritic sst1 receptors in the arcuate nucleus are ideally poised to mediate SRIF's modulation of afferent synaptic inputs, including central SRIF effects on growth hormone-releasing hormone neurons documented in this area.
Sujet(s)
Hypothalamus/métabolisme , Récepteur somatostatine/métabolisme , Fractions subcellulaires/métabolisme , Animaux , Technique de Western , Cellules COS , Chlorocebus aethiops , Immunohistochimie , Mâle , Microscopie électronique , Rats , Rat Sprague-DawleyRÉSUMÉ
In this study, we investigated whether persistent agonist stimulation of NTS2 receptors gives rise to down-regulation, in light of reports that their activation induced long-lasting effects. To address this issue, we incubated COS-7 cells expressing the rat NTS2 with neurotensin (NT) for up to 24 h and measured resultant cell surface [125I]-NT binding. We found that NTS2-expressing cells retained the same surface receptor density despite efficient internalization mechanisms. This preservation was neither due to NTS2 neosynthesis nor recycling since it was not blocked by cycloheximide or monensin. However, it appeared to involve translocation of spare receptors from internal stores, as NT induced NTS2 migration from trans-Golgi network to endosome-like structures. This stimulation-induced regulation of cell surface NTS2 receptors was even more striking in rat spinal cord neurons. Taken together, these results suggest that sustained NTS2 activation promotes recruitment of intracellular receptors to the cell surface, thereby preventing functional desensitization.
Sujet(s)
Neurotensine/pharmacologie , Récepteur neurotensine/agonistes , Récepteur neurotensine/métabolisme , Animaux , Cellules COS , Membrane cellulaire/métabolisme , Chlorocebus aethiops , Régulation négative , Appareil de Golgi/métabolisme , Humains , Cinétique , Mâle , Neurones/métabolisme , Neurotensine/administration et posologie , Transport des protéines , Rats , Rat Sprague-Dawley , Moelle spinale/cytologieRÉSUMÉ
The present study demonstrates that perikaryaldelta-opioid receptors (deltaORs) in rat dorsal root ganglion (DRG) neurons bind and internalize opioid ligands circulating in the CSF. Using confocal and electron microscopy, we found that prolonged morphine treatment increased the cell surface density of these perikaryal deltaORs and, by way of consequence, receptor-mediated internalization of the fluorescent deltorphin (DLT) analog omega-Bodipy 576/589 deltorphin-I 5-aminopentylamide (Fluo-DLT) in all three types of DRG neurons (small, medium, and large). In contrast, chronic inflammatory pain induced by the injection of complete Freund's adjuvant (CFA) into one hindpaw selectively increased Fluo-DLT internalization in small and medium-sized DRG neurons ipsilateral to the inflammation. Based on our previous studies in the spinal cord of mu-opioid receptor (muOR) knock-out mice, it may be assumed that the enhanced membrane recruitment of deltaORs observed after sustained morphine is attributable to stimulation of muORs. However, the selectivity of the effect induced by inflammatory pain suggests that it involves a different mechanism, namely a modality-specific and pain-related activation of C and Adelta fibers. Indeed, stimulation by capsaicin of transient receptor potential vanilloid 1 receptors, which are selectively expressed by small diameter (< 600 microm2) DRG neurons, increased Fluo-DLT internalization exclusively in this cell population. The present results, therefore, demonstrate that DRG neurons express perikaryal deltaORs accessible to CSF-circulating ligands and that the density and, hence, presumably also the responsiveness, of these receptors may be modulated by both pain-related stimuli and sustained exposure to muOR agonists.
Sujet(s)
Ganglions sensitifs des nerfs spinaux/effets des médicaments et des substances chimiques , Ganglions sensitifs des nerfs spinaux/métabolisme , Morphine/pharmacologie , Mesure de la douleur/effets des médicaments et des substances chimiques , Récepteur delta/analyse , Récepteur delta/biosynthèse , Animaux , Membrane cellulaire/effets des médicaments et des substances chimiques , Membrane cellulaire/métabolisme , Cellules cultivées , Relation dose-effet des médicaments , Ganglions sensitifs des nerfs spinaux/cytologie , Mâle , Morphine/usage thérapeutique , Douleur/traitement médicamenteux , Douleur/métabolisme , Mesure de la douleur/méthodes , Rats , Rat Sprague-Dawley , Récepteur delta/physiologieRÉSUMÉ
The neurotensin receptor subtype 1 (NTS1) is a G-protein-coupled receptor (GPCR) mediating a large number of central and peripheral effects of neurotensin. Upon stimulation, NTS1 is rapidly internalized and targeted to lysosomes. This process depends on the interaction of the phosphorylated receptor with beta-arrestin. Little is known about other accessory endocytic proteins potentially involved. Here, we investigated the involvement of dynamin, amphiphysin, and intersectin in the internalization of NTS1 receptor-ligand complexes in transfected COS-7 and HEK 293 cells, by using the transferrin receptor as an internal control for the constitutive endocytic pathway. We found that NTS1 endocytosis was not only arrestin-dependent, but also dynamin-dependent in both COS-7 and HEK 293 cells, whereas internalization of the transferrin receptor was independent of arrestin but required dynamin. Overexpression of the SH3 domain of amphiphysin II had no effect on receptor internalization in either cell type. By contrast, overexpression of full-length intersectin or of its SH3 domain (but not of its EH domain) inhibited NTS1 internalization in COS-7 but not in HEK 293 cells. This difference between COS-7 and HEK 293 cells was not attributable to differences in endogenous intersectin levels between the two cell lines. Indeed, the same constructs inhibited transferrin endocytosis equally well in COS-7 and HEK 293 cells. However, immunogold electron microscopy revealed that internalized NTS1 receptors were associated with clathrin-coated pits in COS-7 cells but with smooth vesicles in HEK 293 cells, suggesting that NTS1 internalization proceeds via different endocytic pathways in these two cell types.
Sujet(s)
Endocytose , Neurotensine/métabolisme , Récepteur neurotensine/métabolisme , Transduction du signal , Protéines adaptatrices du transport vésiculaire/métabolisme , Animaux , Arrestines/génétique , Arrestines/métabolisme , Cellules COS , Chlorocebus aethiops , Dynamines/génétique , Dynamines/métabolisme , Protéines à fluorescence verte/métabolisme , Humains , Mutation , Protéines de tissu nerveux/métabolisme , Spécificité d'organe , Transport des protéines , Transfection , bêta-ArrestinesRÉSUMÉ
Intrathecal administration of the neuropeptide neurotensin (NT) was shown previously to exert antinociceptive effects in a variety of acute spinal pain paradigms including hotplate, tail-flick, and writhing tests. In the present study, we sought to determine whether some of these antinociceptive effects might be elicited via stimulation of low-affinity NTS2 receptors. We first established, using immunoblotting and immunohistochemical techniques, that NTS2 receptors were extensively associated with putative spinal nociceptive pathways, both at the level of the dorsal root ganglia and of the superficial layers of the dorsal horn of the spinal cord. We then examined the effects of intrathecal administration of NT or selective NTS2 agonists on acute thermal pain. Both NT and NTS2 agonists, levocabastine and Boc-Arg-Arg-Pro-Tyrpsi(CH2NH)Ile-Leu-OH (JMV-431), induced dose-dependent antinociceptive responses in the tail-flick test. The effects of levocabastine and of JMV-431 were unaffected by coadministration of the NTS1-specific antagonist 2-[(1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxy-phenyl)pyrazol-3-yl)carboxylamino]tricyclo)3.3.1.1.(3.7))-decan-2-carboxylic acid (SR48692), confirming that they were NTS2 mediated. In contrast, the antinociceptive effects of NT were partly abolished by coadministration of SR48692, indicating that NTS1 and NTS2 receptors were both involved. These results suggest that NTS2 receptors play a role in the regulation of spinal nociceptive inputs and that selective NTS2 agonists may offer new avenues for the treatment of acute pain.
Sujet(s)
Analgésiques/pharmacologie , Ganglions sensitifs des nerfs spinaux/physiologie , Récepteur neurotensine/physiologie , Moelle spinale/physiologie , Analgésiques/administration et posologie , Animaux , Ganglions sensitifs des nerfs spinaux/effets des médicaments et des substances chimiques , Température élevée , Techniques in vitro , Injections rachidiennes , Vertèbres lombales , Modèles animaux , Neurotensine/pharmacologie , Douleur , Pipéridines/pharmacologie , Rats , Rat Sprague-Dawley , Récepteur neurotensine/effets des médicaments et des substances chimiques , Moelle spinale/effets des médicaments et des substances chimiques , QueueRÉSUMÉ
Apelin is a peptide that was recently isolated as the endogenous ligand for the human orphan APJ receptor, a G protein-coupled receptor which shares 31 % amino-acid sequence identity with the angiotensin type 1 receptor. Apelin naturally occurs in the brain and plasma as 13 (pE13F) and 17 amino-acid (K17F) fragments of a single pro-peptide precursor. In transfected CHO cells, K17F and pE13F bind with high affinity to the rat APJ receptor, promote receptor internalization, and inhibit forskolin-induced cAMP formation. In the same cells, pE13F activates MAP kinase and PI3 kinase pathways. Apelin and APJ receptors are both widely distributed in the brain but are particularly highly expressed in the supraoptic (SON) and paraventricular (PVN) hypothalamic nuclei. Dual labeling studies demonstrate that within these two nuclei, apelin and its receptor are colocalized with vasopressin (AVP) in a subset of magnocellular neurons. In lactating rats, characterized by increases in both synthesis and release of AVP, central injection of apelin inhibits the phasic electrical activity of AVP neurons, reduces plasma AVP levels, and increases aqueous diuresis. Moreover, water deprivation, while increasing the activity of AVP neurons, reduces plasma apelin concentrations and induces an intra-neuronal pile up of the peptide, thereby decreasing the inhibitory effect of apelin on AVP release and preventing additional water loss at the kidney level. Taken together, these data demonstrate that apelin counteracts the effects of AVP in the maintenance of body fluid homeostasis. In addition, apelin and its receptor are present in the cardiovascular system, i.e. heart, kidney and vessels. Systemically administered apelin reduces arterial blood pressure, increases cardiac contractility and reduces cardiac loading. The development of non peptidic analogs of apelin may therefore offer new therapeutic avenues for the treatment of cardiovascular disorders.
Sujet(s)
Protéines de transport/physiologie , Neuropeptides/physiologie , Vasopressines/métabolisme , Séquence d'acides aminés , Animaux , Apeline , Liquides biologiques/physiologie , Encéphale/physiologie , Séquence conservée , Homéostasie , Humains , Protéines et peptides de signalisation intercellulaire , Ligands , Données de séquences moléculaires , Alignement de séquences , Similitude de séquences d'acides aminés , Vasopressines/antagonistes et inhibiteursRÉSUMÉ
By yeast two-hybrid screening we have identified interaction partners for the intracellular C-terminal tail of the human and rodent somatostatin receptor subtype 5 (SSTR5). Interactions with the PDZ domain-containing proteins PIST and PDZK1 are mediated by the PDZ ligand motif at the C terminus of the receptor; in case of the human and mouse (but not the rat) receptors, a slight sequence variation of this motif also allows for binding of the peroxisomal receptor PEX5. PIST is Golgi-associated and retains SSTR5 in the Golgi apparatus when coexpressed with the receptor; PDZK1 on the other hand associates with the SSTR5 at the plasma membrane. Endogenous SSTR5 in the neuroendocrine AtT-20 tumor cell line is colocalized with PIST in the Golgi apparatus. On a functional level, removal of the PDZ ligand motif of the receptor does not interfere with agonist-dependent internalization of the receptor or its targeting to a Golgi-associated compartment; however, recycling of the receptor to the plasma membrane after washout of the agonist is inhibited, suggesting that the PDZ-mediated interaction of SSTR5 is required for postendocytic sorting.
Sujet(s)
Protéines de transport/composition chimique , Protéines membranaires/composition chimique , Récepteur somatostatine/composition chimique , Protéines adaptatrices de la transduction du signal , Motifs d'acides aminés , Séquence d'acides aminés , Animaux , Protéines de transport/métabolisme , Lignée cellulaire , Lignée cellulaire tumorale , Membrane cellulaire/métabolisme , ADN complémentaire/métabolisme , Endocytose , Glutathione transferase/métabolisme , Appareil de Golgi/métabolisme , Protéines de la matrice Golgienne , Protéines à fluorescence verte/métabolisme , Humains , Immunohistochimie , Immunoprécipitation , Insuline/métabolisme , Protéines et peptides de signalisation intracellulaire , Ligands , Protéines membranaires/métabolisme , Protéines de transport membranaire , Souris , Données de séquences moléculaires , Liaison aux protéines , Structure tertiaire des protéines , Récepteur somatostatine/métabolisme , Protéines de fusion recombinantes/composition chimique , Protéines de fusion recombinantes/métabolisme , Techniques de double hybrideRÉSUMÉ
In recent years, we demonstrated that prolonged (48-h) treatment of rats or mice with selective m-opioid receptor ((mu)OR) agonists induced a translocation of delta-opioid receptors ((delta)ORs) from intracellular compartments to neuronal plasma membranes in the dorsal horn of the spinal cord. It remained to be determined whether this phenomenon also occurred in the brain. To resolve this issue, we analyzed by immunogold histochemistry the subcellular distribution of (delta)ORs in the nucleus accumbens, dorsal neostriatum, and frontal cortex in mice treated or not with morphine (48 h). We observed that prolonged treatment with morphine induced a translocation of (delta)ORs from intracellular to subplasmalemmal and membrane compartments in dendrites from both the nucleus accumbens and the dorsal neostriatum but not from the frontal cortex. We propose that this (mu)OR-(delta)OR interaction might prolong and modulate the sensitivity of neurons to opiates in specific target regions.
Sujet(s)
Analgésiques morphiniques/pharmacologie , Morphine/pharmacologie , Néostriatum/effets des médicaments et des substances chimiques , Noyau accumbens/effets des médicaments et des substances chimiques , Récepteur delta/métabolisme , Animaux , Membrane cellulaire/métabolisme , Membrane cellulaire/ultrastructure , Femelle , Lobe frontal/cytologie , Lobe frontal/effets des médicaments et des substances chimiques , Lobe frontal/métabolisme , Mâle , Souris , Souris de lignée C57BL , Microscopie électronique , Néostriatum/cytologie , Néostriatum/métabolisme , Neurones/effets des médicaments et des substances chimiques , Neurones/métabolisme , Neurones/ultrastructure , Noyau accumbens/cytologie , Noyau accumbens/métabolisme , Transport des protéines/effets des médicaments et des substances chimiquesRÉSUMÉ
The present study demonstrated that alternative splicing of the rat nts2 receptor gene generates a 5-transmembrane domain variant isoform (vNTS2) that is co-expressed with the full-length NTS2 receptor throughout the brain and spinal cord, as evidenced by reverse transcription-PCR. The vNTS2 polypeptide is 281 amino acids in length, which is 135 amino acids shorter than the full-length isoform. Immunohistochemical and radioligand binding studies revealed that the HA-tagged recombinant vNTS2 receptor is poorly targeted to plasma membranes in transfected COS-7 cells. Binding studies also showed that the truncated receptor displayed a 5000-fold lower affinity for neurotensin (NT) than its full-length counterpart (IC(50) of 10 mum and 2 nm, respectively). Yet NT binding induced efficient internalization of receptor-ligand complexes in vNTS2-transfected cells. Furthermore, it produced a rapid (<5 min) activation of the mitogen-activated protein kinases (ERK1/2) pathway, indicating functional coupling of the variant receptor. This activation is sustained (>1 h) and is also produced by the NTS2 agonist levocabastine. Western blotting experiments suggested that vNTS2 is not expressed in monomeric form in the rat central nervous system. However, it does appear to form a variety of multimeric complexes, including homodimers and heterodimers, with the full-length NTS2. Indeed, co-immunoprecipitation studies in dually transfected cells demonstrated that the two receptor isoforms can form stable associations. Taken together, the present results indicated that the rat vNTS2 is a functional receptor that may play a role in NT signaling in mammalian central nervous system.
Sujet(s)
Système nerveux central/métabolisme , Neurotensine/composition chimique , Récepteur neurotensine/composition chimique , Récepteur neurotensine/métabolisme , Épissage alternatif , Séquence d'acides aminés , Animaux , Fixation compétitive , Technique de Western , Encéphale/métabolisme , Cellules CHO , Cellules COS , Lignée cellulaire , Cricetinae , ADN complémentaire/métabolisme , Densitométrie , Dimérisation , Relation dose-effet des médicaments , Épitopes/composition chimique , Immunotransfert , Immunohistochimie , Immunoprécipitation , Concentration inhibitrice 50 , Ligands , Mitogen-Activated Protein Kinase 1/métabolisme , Mitogen-Activated Protein Kinase 3/métabolisme , Données de séquences moléculaires , Peptides/composition chimique , Pipéridines/pharmacologie , Liaison aux protéines , Isoformes de protéines , Structure tertiaire des protéines , ARN messager/métabolisme , Rats , RT-PCR , Similitude de séquences d'acides aminés , Transduction du signal , Moelle spinale/métabolisme , Facteurs temps , Distribution tissulaire , TransfectionRÉSUMÉ
The neuronal isoform of vesicular monoamine transporter, VMAT2, is responsible for packaging dopamine and other monoamines into synaptic vesicles and thereby plays an essential role in dopamine neurotransmission. Dopamine neurons in mice lacking VMAT2 are unable to store or release dopamine from their synaptic vesicles. To determine how VMAT2-mediated filling influences synaptic vesicle morphology and function, we examined dopamine terminals from VMAT2 knockout mice. In contrast to the abnormalities reported in glutamatergic terminals of mice lacking VGLUT1, the corresponding vesicular transporter for glutamate, we found that the ultrastructure of dopamine terminals and synaptic vesicles in VMAT2 knockout mice were indistinguishable from wild type. Using the activity-dependent dyes FM1-43 and FM2-10, we also found that synaptic vesicles in dopamine neurons lacking VMAT2 undergo endocytosis and exocytosis with kinetics identical to those seen in wild-type neurons. Together, these results demonstrate that dopamine synaptic vesicle biogenesis and cycling are independent of vesicle filling with transmitter. By demonstrating that such empty synaptic vesicles can cycle at the nerve terminal, our study suggests that physiological changes in VMAT2 levels or trafficking at the synapse may regulate dopamine release by altering the ratio of fillable-to-empty synaptic vesicles, as both continue to cycle in response to neural activity.
Sujet(s)
Dopamine/métabolisme , Glycoprotéines membranaires/génétique , Protéines de transport membranaire/génétique , Neurones/métabolisme , Vésicules synaptiques/physiologie , Animaux , Encéphale/métabolisme , Agents colorants/pharmacologie , Endocytose , Acide glutamique/métabolisme , Cinétique , Mésencéphale/métabolisme , Mésencéphale/ultrastructure , Souris , Souris knockout , Microscopie électronique à transmission , Microscopie de fluorescence , Neurones/ultrastructure , Isoformes de protéines , Synapses/métabolisme , Facteurs temps , Transporteurs vésiculaires des amines biogènes , Transporteurs vésiculaires des monoaminesRÉSUMÉ
The role and signaling properties of the low-affinity neurotensin receptor (NTS2) are still controversial. In particular, it is unclear whether neurotensin acts as an agonist, inverse agonist, or antagonist at this site. In view of the growing evidence for a role of NTS2 in antinociception, the elucidation of the pharmacological and coupling properties of this receptor is particularly critical. In the present study, we demonstrate that in Chinese hamster ovary (CHO) cells expressing the rat NTS2 receptor, neurotensin (NT), levocabastine, neuromedin N, and the high-affinity NT receptor antagonist SR48692 [2-[[1-(-7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid] all bind to and activate the NTS2 receptor. This activation is followed by ligand-induced internalization of receptor-ligand complexes, as evidenced by confocal microscopy using a fluorescent NT analog. All compounds tested produced a rapid and sustained activation of extracellular signal-regulated kinases 1/2 (ERK1/2) but were without specific effect on Ca(2+) mobilization. The agonist-induced activation of ERK1/2 was completely abolished by preincubation of the cells with the endocytosis inhibitors phenylarsine oxide and monodansylcadaverine as well as overexpression of a dominant-negative mutant of dynamin 1 (DynK44A), indicating that receptor internalization was required for ERK1/2 activation. NTS2-induced activation of ERK1/2 was not species-specific, because the same agonistic effects of NT and analogs were observed in CHO cells transfected with the human NTS2 receptor. In conclusion, this study demonstrates that NTS2 is a bona fide NT receptor and that activation of this receptor by NT or NT analogs results in an internalization-dependent activation of the ERK1/2 signaling cascade.
Sujet(s)
Calcium/physiologie , Récepteur neurotensine/physiologie , Animaux , Séquence nucléotidique , Cellules CHO , Cricetinae , Amorces ADN , Activation enzymatique , Antihistaminiques des récepteurs H1/pharmacologie , Cinétique , Système de signalisation des MAP kinases/effets des médicaments et des substances chimiques , Système de signalisation des MAP kinases/physiologie , Mitogen-Activated Protein Kinase 1/métabolisme , Mitogen-Activated Protein Kinase 3/métabolisme , Neurotensine/analogues et dérivés , Neurotensine/pharmacologie , Pipéridines/pharmacologie , Rats , Récepteur neurotensine/génétique , Protéines recombinantes/métabolisme , RT-PCR , TransfectionRÉSUMÉ
The neurotensin receptor-3, originally identified as sortilin, is unique among neuropeptide receptors in that it is a single trans-membrane domain, type I receptor. To gain insight into the functionality of neurotensin receptor-3, we examined the neurotensin-induced intracellular trafficking of this receptor in the human carcinoma cell line HT29, which expresses both neurotensin receptor-1 and -3 sub-types. At steady state, neurotensin receptor-3 was found by sub-cellular fractionation and electron microscopic techniques to be predominantly associated with intracellular elements. A small proportion (approximately 10%) was associated with the plasma membrane, but a significant amount (approximately 25%) was observed inside the nucleus. Following stimulation with neurotensin (NT), neurotensin/neurotensin receptor-3 complexes were internalized via the endosomal pathway. This internalization entailed no detectable loss of cell surface receptors, suggesting compensation through either recycling or intracellular receptor recruitment mechanisms. Internalized ligand and receptors were both sorted to the pericentriolar recycling endosome/Trans-Golgi Network (TGN), indicating that internalized neurotensin is sorted to this compartment via neurotensin receptor-3. Furthermore, within the Trans-Golgi Network, neurotensin was bound to a lower molecular form of the receptor than at the cell surface or in early endosomes, suggesting that signaling and transport functions of neurotensin receptor-3 may be mediated through different molecular forms of the protein. In conclusion, the present work suggests that the neurotensin receptor-3 exists in two distinct forms in HT29 cells: a high molecular weight, membrane-associated form responsible for neurotensin endocytosis from the cell surface and a lower molecular weight, intracellular form responsible for the sorting of internalized neurotensin to the Trans-Golgi Network.
Sujet(s)
Membrane cellulaire/métabolisme , Endocytose/physiologie , Glycoprotéines membranaires/métabolisme , Protéines de tissu nerveux/métabolisme , Transport des protéines/physiologie , Récepteur neurotensine/métabolisme , Protéines adaptatrices du transport vésiculaire , Fractionnement cellulaire , Noyau de la cellule/métabolisme , Appareil de Golgi/métabolisme , Cellules HT29 , Humains , Microscopie immunoélectronique , Neurotensine/métabolisme , Transduction du signal/physiologieRÉSUMÉ
An in vivo fluorescent deltorphin (Fluo-DLT) internalization assay was used to assess the distribution and regulation of pharmacologically available delta opioid receptors (deltaORs) in the rat lumbar (L4-5) spinal cord. Under basal conditions, intrathecal injection of Fluo-DLT resulted in the labeling of numerous deltaOR-internalizing neurons throughout dorsal and ventral horns. The distribution and number of Fluo-DLT-labeled perikaryal profiles were consistent with that of deltaOR-expressing neurons, as revealed by in situ hybridization and immunohistochemistry, suggesting that a large proportion of these cells was responsive to intrathecally administered deltaOR agonists. Pretreatment of rats with morphine for 48 hr resulted in a selective increase in Fluo-DLT-labeled perikaryal profiles within the dorsal horn. These changes were not accompanied by corresponding augmentations in either deltaOR mRNA or (125)I-deltorphin-II binding levels, suggesting that they were attributable to higher densities of cell surface deltaOR available for internalization rather than to enhanced production of the receptor. Unilateral dorsal rhizotomy also resulted in increased Fluo-DLT internalization in the ipsilateral dorsal horn when compared with the side contralateral to the deafferentation or to non-deafferented controls, suggesting that deltaOR trafficking in dorsal horn neurons may be regulated by afferent inputs. Furthermore, morphine treatment no longer increased Fluo-DLT internalization on either side of the spinal cord after unilateral dorsal rhizotomy, indicating that microOR-induced changes in the cell surface availability of deltaOR depend on the integrity of primary afferent inputs. Together, these results suggest that regulation of deltaOR responsiveness through microOR activation in this region is linked to somatosensory information processing.